BDSX Biodesix, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
13:58
Jan 03
Jan 03
Undervalued medical testing name with EBITDA inflection and revenue growth
BDSX is guided to rotate from EBITDA negative to EBITDA positive in Q4 and then likely positive all 2026. Revenue is growing 25%+ in the medical testing industry. The author believes it should trade at 4x to 5x forward sales like peers such as WGS, but currently trades below 1x forward sales, implying significant upside as the market reprices it.
HIGH
About BDSX Investor Commentary
Across the available history and selected sources, Buzzberg tracks BDSX (Biodesix, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Tripper4432.